Tonix Pharmaceuticals is focused on advancing science to improve patient care and public health. We are developing novel therapeutics for a range of disorders, in addition to vaccines and antivirals for pandemic preparedness and biodefense. As a patient-focused biopharmaceutical company, Tonix’s primary goal is the betterment of patient lives.
Tonix is dedicated to finding cures for difficult to treat, widely occurring, chronic disorders of the central nervous system including pain, neurological, psychiatric and addiction conditions.* Our goal is to heal sufferings of millions through scientific advancements.
We are advancing scientific programs that focus on therapeutics to prevent organ transplant rejection, to manage autoimmune conditions, and to improve responses to immunotherapy in certain cancers.*
Tonix’s infectious disease portfolio targets pathogenic infections, including the ongoing COVID-19 pandemic. Tonix is attacking COVID-19 using vaccines, antivirals and a Long COVID therapeutic.* Pandemic preparedness is necessary to combat infections like SARS-CoV-2.
Tonix is committed to improving patient care, including for those suffering from rare diseases and for which no drug has been approved. Rare diseases are often caused by genetic disorders and are characterized by complex symptoms. A rare disease is a condition that affects fewer than 200,000 people in the US as defined in the Orphan Drug Act of 1983.